• All compounds were metabolized by at least one CYP450 enzyme (77% by CYP3A) • 77% showed possible inhibition or induction of ≥ 1 metabolizing enzyme in vitro; 85% showed a possible interaction with ≥ 1 transport protein in vitro • Overall, 45% had a metabolism-based DDI that resulted in a change in exposure of clinical significance 
Drug blood levels
Efflux of drug back into the gut
Altered Absorption: Transport Proteins in Intestinal Lumen
• Uptake and efflux transporters in the gut can be inhibited or induced by drugs, which may ↑ or ↓ bioavailability of drugs that rely on the transporters (i.e. substrates) • Reliance on uptake/efflux transporters for absorption depends largely on compound permeability  The lower the permeability of a compound, the more its absorption is affected by membrane transporters. • Of the many gut transporters, only 2 are generally associated with clinical DDIs:
• P-glycoprotein (P-gp, MDR1, ABCB1)
• Breast Cancer Resistance Protein (BCRP, ABCG2)
• E.g. DDI between quinidine (P-gp inhibitor) and digoxin (sensitive substrate) is well documented. In a perfusion catheter study, quinidine caused a 2.5-fold increase in the amount of digoxin absorbed 1 • Digoxin DDI studies are often conducted as part of development for new drugs found to be potential P-gp inhibitors in vitro • Clinical P-gp inhibitors include: cyclosporine, erythromycin, verapamil, itraconazole, and others Altered Distribution: Protein Binding
• Theoretical mechanism of DDI for restrictively cleared drugs (i.e. small fraction of drug is extracted during passage through eliminating organ) • Only unbound drug in plasma is cleared. Thus, ↑ fu leads to an increase in total drug CL (and ↓ in plasma concentrations) • However, unbound plasma concentrations typically return to pre-displacement values after a transient increase
• Only likely to be clinically significant for drugs with high protein binding, small V d , and narrow therapeutic index (e.g. warfarin)
• "…the overall clinical importance of plasma protein binding displacement interactions continues to be overstated…" • Determine if study drug causes inhibition or induction of enzymes or transporters? -Describes study drug potential as a "perpetrator"
Predicting Clinical DDIs, cont.
• If inhibition/induction of enzymes or transporters is observed in vitro, the probability of an in vivo effect is determined:
• Concentration at which inhibition or induction is observed in vitro (e.g. IC50) is compared to in vivo concentrations (e.g. Cmax or [I])
• If inhibition/induction is possible (e.g.
[I]/IC50 > 0.1), clinical DDI studies must be considered, or mechanistic modeling may be performed to evaluate potential for DDI in vivo Assessing Clinical DDIs: Phase 1 studies
• Initially probe DDI studies are performed:
• For a substrate, assess effect of a strong inhibitor (e.g. Itraconazole for CYP3A) and strong inducer (e.g. Rifampin for CYP3A) on the study drug • For a potential perpetrator, assess effect on a sensitive substrate (e.g. single dose oral midazolam for CYP3A; digoxin for P-gp; rosuvastatin for OATP1B1)
• Depending on results of these initial studies, addt'l DDI studies should be considered: Ivacaftor is a sensitive CYP3A substrate. Co-administration with ketoconazole, a strong CYP3A inhibitor, significantly increased ivacaftor exposure [measured as area under the curve (AUC)] by 8.5-fold. Based on simulations of these results, a reduction of the KALYDECO dose to 150 mg twice a week is recommended for co-administration with strong CYP3A inhibitors, such as ketoconazole, itraconazole, posaconazole, voriconazole, telithromycin, and clarithromycin.
Co-administration with fluconazole, a moderate inhibitor of CYP3A, increased ivacaftor exposure by 3-fold. Therefore, a reduction of the KALYDECO dose to 150 mg once daily is recommended for patients taking concomitant moderate CYP3A inhibitors, such as fluconazole and erythromycin.
Co-administration of KALYDECO with grapefruit juice, which contains one or more components that moderately inhibit CYP3A, may increase exposure of ivacaftor. Therefore, food containing grapefruit or Seville oranges should be avoided during treatment with KALYDECO [see Clinical Pharmacology (12. 3)].
7.2
Inducers of CYP3A Co-administration with rifampin, a strong CYP3A inducer, significantly decreased ivacaftor exposure (AUC) by approximately 9-fold. Therefore, co-administration with strong CYP3A inducers, such as rifampin, rifabutin, phenobarbital, carbamazepine, phenytoin, and St. John's Wort is not recommended [see Warnings and Precautions (5.2) and Clinical Pharmacology (12.3)].
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